Letter to the Editor: Response to Fitzgerald T et al. Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA

Dermatol Ther (Heidelb). 2023 Nov;13(11):2911-2916. doi: 10.1007/s13555-023-01015-w. Epub 2023 Sep 26.
No abstract available

Keywords: Claims data; Clinical interpretation; Methodology; Persistence; Psoriasis.

Publication types

  • Letter
  • Comment